Purple Biotech Newsroom

Purple Biotech Analyst Ratings

BenzingaNov 15 14:44 ET

Purple Biotech Analyst Ratings

BenzingaSep 20 13:34 ET

H.C. Wainwright Maintains Purple Biotech(PPBT.US) With Buy Rating, Cuts Target Price to $33

Moomoo NewsSep 19 06:31 ET

HC Wainwright & Co. Maintains Buy on Purple Biotech, Lowers Price Target to $8

BenzingaSep 19 06:29 ET

Analysts Offer Insights on Healthcare Companies: Purple Biotech (PPBT) and Aligos Therapeutics (ALGS)

TipRanksAug 20 04:12 ET

Purple Biotech Analyst Ratings

BenzingaAug 19 07:44 ET

Purple Biotech Analyst Ratings

BenzingaJul 11 13:24 ET

Promising Phase 2 Results for Purple Biotech's CM24 in Pancreatic Cancer Treatment Bolster Buy Rating

TipRanksJul 11 12:20 ET

Buy Rating Justified by Purple Biotech's Promising Clinical Data and Market Potential

TipRanksMay 21 11:50 ET

Purple Biotech Analyst Ratings

BenzingaMay 21 11:37 ET

HC Wainwright & Co. Reiterates Buy on Purple Biotech, Maintains $10 Price Target

BenzingaMay 21 11:36 ET

Purple Biotech Analyst Ratings

BenzingaApr 26 14:26 ET

Purple Biotech Analyst Ratings

BenzingaMar 7 13:57 ET

Purple Biotech Analyst Ratings

BenzingaMar 5 12:10 ET

Promising Pipeline Prospects for Purple Biotech: Buy Rating Affirmed Amidst Anticipated Clinical Advancements

TipRanksMar 5 11:41 ET

Purple Biotech Analyst Ratings

BenzingaFeb 27 12:44 ET

Buy Rating Justified by Promising Phase 1 Results of Purple Biotech's NT219 in SCCHN Treatment

TipRanksFeb 27 12:25 ET

Analysts Offer Insights on Healthcare Companies: Purple Biotech (PPBT) and Sanofi (OtherSNYNF)

TipRanksFeb 1 10:40 ET

Purple Biotech Analyst Ratings

BenzingaNov 21, 2023 13:44 ET

Promising Clinical Trial Results and Accelerated Enrollment Boost Purple Biotech's Buy Rating

TipRanksNov 21, 2023 11:35 ET